Every material Form 8-K Enveric Biosciences, Inc. has filed with the SEC since June 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, and cash on hand of $8.3 million as of June 30, 2026. The company also gave an update on its lead drug candidate EB-003, including preclinical data and the start of genotoxicity studies ahead of a planned IND submission.
Net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, versus $2.5 million a year earlier.
Basic and diluted loss per share was $0.76, compared with $11.65 in the second quarter of 2025.
The company raised $5.0 million in gross offering proceeds and $1.5 million from warrant exercises in the quarter.
Genotoxicity studies for EB-003 were initiated, a step the filing describes as required for IND submission.
Enveric Biosciences filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock through its existing at-the-market sales agreement with H.C. Wainwright & Co. The company has previously sold $4,483,711.04 of shares under that agreement, which dates to April 9, 2025. The filing adds to potential dilution for existing shareholders, but it does not disclose a financial result or a change in business operations.
Additional offering amount: $2,425,000 of common stock under the ATM Agreement dated April 9, 2025
Sales to date under the ATM Agreement before this filing: $4,483,711.04
Sales agent: H.C. Wainwright & Co., LLC; legal opinion filed as Exhibit 5.1 from Greenberg Traurig, LLP
Enveric Biosciences filed a Form 8-K furnishing an investor presentation, labeled Q2 2026, that management intends to post on its website on or about June 8, 2026. The filing contains no financial results, guidance, or transaction terms, and the company states the information is not deemed filed under Section 18 of the Exchange Act.
Investor presentation furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure)
Presentation is labeled Investor Presentation Q2 2026 and is available at enveric.com/investors/events
Company says it may reuse the presentation with possible modifications for investors, analysts, lenders, and others
8-K signed by CEO Joseph Tucker, Ph.D. on June 8, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Enveric Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →